Literature DB >> 10225735

Immunoadsorption for the treatment of bullous pemphigoid.

N Ino1, N Kamata, C Matsuura, H Shinkai, M Odaka.   

Abstract

We treated 2 intractable patients with pemphigoid by absorbent plasmapheresis using dextran sulfate conjugated cellulose columns with an automated regenerating unit. During a 2 week period, this plasmapheresis was performed 4 to 6 times for Cases 1 and 2, respectively. Clinical findings including skin eruptions were remarkably improved, and the titers of antibasement membrane zone antibodies were decreased after the treatment of 1.8 to 4.2 L of plasma. These results suggest that the absorbent column is effective for intractable pemphigoid.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 10225735     DOI: 10.1111/j.1744-9987.1997.tb00059.x

Source DB:  PubMed          Journal:  Ther Apher        ISSN: 1091-6660


  5 in total

Review 1.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

Review 2.  Clinical and serological responses following plasmapheresis in bullous pemphigoid: two case reports and a review of the literature.

Authors:  Brian Chang; Ashok Tholpady; Richard S P Huang; Elena Nedelcu; Yu Bai
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

Review 3.  Drug Development in Pemphigoid Diseases.

Authors:  Katja Bieber; Ralf J Ludwig
Journal:  Acta Derm Venereol       Date:  2020-02-12       Impact factor: 3.875

Review 4.  Rituximab therapy in pemphigus and other autoantibody-mediated diseases.

Authors:  Nina A Ran; Aimee S Payne
Journal:  F1000Res       Date:  2017-01-27

Review 5.  Proteases in Pemphigoid Diseases.

Authors:  Sho Hiroyasu; Christopher T Turner; Katlyn C Richardson; David J Granville
Journal:  Front Immunol       Date:  2019-06-26       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.